[1] Uk N C G C. Osteoarthritis: Care and Management in Adults[M]. London: National Institute for Health and Care Excellence (UK), 2014.
[2] Mcalindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis[J]. Osteoarthritis Cartilage, 2014, 22(3):363-388.
[3] 中华医学会风湿病分会. 骨关节炎诊治指南(草案)[J]. 中华风湿病学杂志, 2005, (9):22-24.
[4] 袁长深,梅其杰,郭锦荣,等. 缓解膝骨关节炎的中医外治疗法的近况[J]. 时珍国医国药, 2013, 24(8):1984-1985.
[5] 方锐,孟庆才,邓迎杰,等. 膝骨关节炎患者血清和关节液中基质金属蛋白酶1,3、基质金属蛋白酶抑制剂1及白细胞介素1β含量与补肾通络方的干预[J]. 中国组织工程研究与临床康复, 2008, 28(12):5581-5585.
[6] 肖会. 苗药组方熏洗对家兔早期膝骨关节炎模型软骨细胞凋亡与增殖影响的实验研究[D]. 贵阳中医学院, 2012:39-40.
[7] 宁显明,樊粤光,徐传毅,等. 补肾中药对膝骨关节炎软骨TGF-β1表达的影响[J]. 中国中医骨伤科杂志, 2004, 12(1):36-38.
[8] Fang PK, Ma XC, Ma DL, et al. Determination of interleukin-1 receptor antagonist, interleukin-10, and transforming growth factor-beta1 in synovial fluid aspirates of patients with temporomandibular disorders[J]. J Oral Maxillofac Surg,1999, 57(8):928-929.
[9] 陈志达,林瀚洋,余志毅,等. 膝骨关节炎动物模型研究进展[J]. 风湿病与关节炎, 2016, 5(1):67-70.
[10] 张金山,程圆圆,刘健. 膝骨关节炎患者血清IL-1β、TGF-β变化及相关性研究[J]. 江西中医药大学学报, 2011,23 (6):29-32.
[11] Frenkel SR, Saadeh PB, Mehrara BJ, et al. Transforming growth factor beta superfamily members: role in cartilage modeling[J]. Plast Reconstr Surg, 2000, 105(3):980-990.
[12]Long E, Motwani R, Reece D, et al. The role of TGF-ss1 in osteoarthritis of the temporomandibular joint in two genetic mouse models[J]. Arch Oral Biol, 2016, 67(7):68-73.
[13]Fang J, Xu L, Li Y, et al. Roles of TGF-beta 1 signaling in the development of osteoarthritis[J]. Histol Histopathol, 2016, 31(11):11779.
[14] 林燕云,林木南,李西海,等. 中药熏洗治疗膝骨性关节炎的临床研究[J]. 福建中医药, 2010, 41(1):22-23.
[15] 林小武. 中药熏洗治疗膝骨性关节炎的研究近况[J]. 中医外治杂志, 2010, 19(4):45-47.
[16] Chen B, Zhan H, Chung M, et al. Chinese herbal bath therapy for the treatment of knee osteoarthritis: meta-analysis of randomized controlled trials[J]. Evid Based Complement Alternat Med, 2015, 2015(9):1-12. |